NEW YORK, December 30, 2022 (GLOBE NEWSWIRE) — Bragar Eagel & Squire, PC, a nationally recognized shareholder rights law firm, is investigating potential claims against Design Therapeutics, Inc. (“Design” or the “Company”) DSGN on behalf of the design shareholders. Our investigation concerns whether Design has violated federal securities laws and/or engaged in other illegal business practices.

click here to take part in the action.

On or about March 24, 2021, Design completed its initial public offering (“IPO”), selling 12 million shares at a price of $20.00 per share. Then, on December 7, 2022, Design released initial data from a Phase 1 study of DT-216 in patients with Friedreich’s Ataxia. Among other findings, Design said that 16 patients on DT-216 and eight on placebo reported at least one treatment-emergent adverse event.

As a result of this news, Design’s share price fell sharply during intraday trading on December 8, 2022.

If you have purchased or otherwise acquired Design Stock and have suffered a loss, are a long-term shareholder, have information, would like to learn more about these claims, or have any questions about this announcement or your rights or interests in relation to these matters, please contact us Brandon Walker or Melissa Fortunato via email at investigations@bespc.comby phone at (212) 355-4648 or by fill out this contact form. There are no costs or obligations for you.

About Bragar Eagle & Squire, PC:

Bragar Eagel & Squire, PC is a nationally recognized law firm with offices in New York and California. The firm represents individual and institutional investors in commercial, securities, derivatives and other complex litigation in state and federal courts across the country. More information about the company can be found at www.bespc.com. attorney advertising. Previous results do not guarantee similar results.

Contact information:

Bragar Eagle & Squire, PC
Brandon Walker, Esq.
Melissa Fortunato, Esq.
(212) 355-4648
investigations@bespc.com
www.bespc.com

[ad_2]

Source story